GET(T)ING(E) BEYOND THE SHORT-TERM TROUBLES (BUY; 51% UPSIDE)
17/06/22 -" Getinge’s (Buy, Sweden) journey on the bourses has been a story of two extremes since we zeroed in on it in January 2021. While the stock rode the multiple earnings surprises to all-time highs ..."
Pages
63
Language
English
Published on
17/06/22
You may also be interested by these reports :
27/02/26
bioMerieux’s Q4 sales met expectations, with top-line growth driven by both segments. Management fulfilled its 2025 commitments and provided 2026 ...
25/02/26
Even though Q4 sales and profitability missed consensus, the markets seem happy with the 2026 outlook. Q4 performance was underpinned by healthy ...
25/02/26
Fresenius delivered solid Q4 25 results, supported by broad-based growth across Kabi and Helios. Biopharma remained the key growth engine, supported ...
24/02/26
FMC delivered a strong Q4 profit beat, with record profitability driven by accelerated FME25+ savings and operational discipline. FY 25 results also ...